Cargando…

Levels of circulating semaglutide determine reductions in HbA1c and body weight in people with type 2 diabetes

Glucagon-like peptide-1 receptor agonists (GLP-1RA) are used for the treatment of type 2 diabetes. Whether clinically important responses and adverse events (AEs) are dependent on the route of administration has not been determined. We demonstrate that nearly identical exposure-response pharmacodyna...

Descripción completa

Detalles Bibliográficos
Autores principales:	Overgaard, Rune V., Hertz, Christin L., Ingwersen, Steen H., Navarria, Andrea, Drucker, Daniel J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8484505/ https://www.ncbi.nlm.nih.gov/pubmed/34622228 http://dx.doi.org/10.1016/j.xcrm.2021.100387

Ejemplares similares

Impact on HbA1c and body weight of switching from other GLP‐1 receptor agonists to semaglutide: A model‐based approach
por: Overgaard, Rune V., et al.
Publicado: (2018)

Clinical Pharmacokinetics of Oral Semaglutide: Analyses of Data from Clinical Pharmacology Trials
por: Overgaard, Rune V., et al.
Publicado: (2021)

Oral Semaglutide Reduces HbA(1c) and Body Weight in Patients with Type 2 Diabetes Regardless of Background Glucose-Lowering Medication: PIONEER Subgroup Analyses
por: Pratley, Richard E., et al.
Publicado: (2021)

Population Pharmacokinetics of Semaglutide for Type 2 Diabetes
por: Overgaard, Rune V., et al.
Publicado: (2019)

Exposure‐response analysis for evaluation of semaglutide dose levels in type 2 diabetes
por: Petri, Kristin C. C., et al.
Publicado: (2018)

Injectable semaglutide and reductions in HbA1c and weight in the real world in people switched from alternative glucagon‐like peptide‐1 receptor agonists
por: Crabtree, Thomas S. J., et al.
Publicado: (2022)

Semaglutide s.c. Once-Weekly in Type 2 Diabetes: A Population Pharmacokinetic Analysis
por: Carlsson Petri, Kristin Cecilie, et al.
Publicado: (2018)

Greater Combined Reductions of HbA(1c) ≥ 1.0% and Body Weight Loss ≥ 5.0% or ≥ 10.0% with Orally Administered Semaglutide Versus Comparators
por: Dungan, Kathleen M., et al.
Publicado: (2023)

Longitudinal Modeling of the Relationship Between Mean Plasma Glucose and HbA1c Following Antidiabetic Treatments
por: Møller, J B, et al.
Publicado: (2013)

Cost of Achieving HbA1c Treatment Targets and Weight Loss Responses with Once-Weekly Semaglutide Versus Dulaglutide in the United States
por: Wilkinson, Lars, et al.
Publicado: (2018)

Abstract 15: Glycemic and body weight responses to oral semaglutide in the PIONEER trial program
por: Kumar, K B Sharan, et al.
Publicado: (2022)

Simultaneous Reduction in Both HbA1c and Body Weight with Canagliflozin Versus Glimepiride in Patients with Type 2 Diabetes on Metformin
por: Leiter, Lawrence A., et al.
Publicado: (2016)

Once-Weekly Semaglutide Reduces HbA(1c) and Body Weight in Patients with Type 2 Diabetes Regardless of Background Common OAD: a Subgroup Analysis from SUSTAIN 2–4 and 10
por: Capehorn, Matthew, et al.
Publicado: (2020)

Measurement of HbA(1c) and HbA(2) by Capillarys 2 Flex Piercing HbA(1c) programme for simultaneous management of diabetes and screening for thalassemia
por: Ke, Peifeng, et al.
Publicado: (2017)

Standardization of the HbA(2) Assay
por: Paleari, Renata, et al.
Publicado: (2018)

A Relative Cost of Control Analysis of Once-Weekly Semaglutide Versus Exenatide Extended-Release and Dulaglutide for Bringing Patients to HbA1c and Weight Loss Treatment Targets in the USA
por: Johansen, Pierre, et al.
Publicado: (2019)

Correction to: A Relative Cost of Control Analysis of Once-Weekly Semaglutide Versus Exenatide Extended-Release and Dulaglutide for Bringing Patients to HbA1c and Weight Loss Treatment Targets in the USA
por: Johansen, Pierre, et al.
Publicado: (2019)

The Impact of Substantial Improvements in HbA1c and Weight Loss on the Medication Preferences of People with Type 2 Diabetes
por: Gelhorn, Heather L, et al.
Publicado: (2023)

HbA(1c): The lower the better?
por: Araki, Eiichi, et al.
Publicado: (2011)

The True Value of HbA1c as a Predictor of Diabetic Complications: Simulations of HbA1c Variables
por: Lind, Marcus, et al.
Publicado: (2009)

Haemoglobin J-Baltimore can be detected by HbA(1c) electropherogram but with underestimated HbA(1c) value
por: Brunel, Valéry, et al.
Publicado: (2016)

Utility of HbA(1c) assessment in people with diabetes awaiting liver transplantation
por: Bhattacharjee, D., et al.
Publicado: (2019)

Albumin of People with Diabetes Mellitus Is More Reduced at Low HbA1c
por: Paar, Margret, et al.
Publicado: (2023)

Influence of Serum Albumin on HbA1c and HbA1c-Defined Glycemic Status: A Retrospective Study
por: Feng, Xiaojing, et al.
Publicado: (2021)

Simulation of a computed HbA(1c) using a weighted average glucose
por: Boutayeb, W., et al.
Publicado: (2016)

Hb H Interference on Measurement Of HbA1c With Ion-Exchange HPLC
por: Agilli, Mehmet, et al.
Publicado: (2013)

Determinants of HbA1c reduction with FreeStyle Libre flash glucose monitoring (FLARE-NL 5)
por: Lameijer, A., et al.
Publicado: (2020)

Drugs affecting HbA1c levels
por: Unnikrishnan, Ranjit, et al.
Publicado: (2012)

Current Status of HbA1c Biosensors
por: Lin, Hua, et al.
Publicado: (2017)

The association of circulating angiogenic factors and HbA1c with the risk of preeclampsia in women with preexisting diabetes
por: Cohen, Allison L., et al.
Publicado: (2014)

Hemoglobin variants detected by hemoglobin A1c (HbA1c) analysis and the effects on HbA1c measurements
por: Nasir, Nadzimah Mohd, et al.
Publicado: (2010)

In-House Algorithm for Reporting Discrepant HbA1c Result and Troubleshooting a Case of False Low HbA1c
por: Pant, Vivek, et al.
Publicado: (2021)

Estimation of mean erythrocyte age using HbA1c or HbA1c/glycated albumin for evaluation of anemia severity
por: Koga, Masafumi, et al.
Publicado: (2023)

Glucose-Independent Ethnic Differences in HbA(1c) in People Without Known Diabetes
por: Hare, Matthew J.L., et al.
Publicado: (2013)

Adverse Changes in HbA1c, Body Weight and Insulin Use in People with Type 1 Diabetes Mellitus Following Dapagliflozin Discontinuation in the DEPICT Clinical Trial Programme
por: Gordon, Jason, et al.
Publicado: (2020)

The Association of Percent Body Fat and Lean Mass With HbA(1c) in US Adults
por: Bower, Julie K., et al.
Publicado: (2017)

Uric acid lowering in relation to HbA1c reductions with the SGLT2 inhibitor tofogliflozin
por: Ouchi, Motoshi, et al.
Publicado: (2018)

Periodontal therapy as an adjunctive modality for HbA1c reduction in type-2 diabetic patients
por: Sundar, Chalini, et al.
Publicado: (2018)

RS12574989 and haplotype associated with α/β-chain imbalance and population HbA2 reduction
por: Lin, Qiyin, et al.
Publicado: (2022)

HbA mutation causing false-normal HbA1c results determined by HPLC in a patient with type 2 diabetes mellitus: A case report
por: Wang, Juan, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_3vi23qvm85nif9o9j6hd4479rb